Table 19Summary tumor response and quality of life, KQ3b

StudyTumor Response (%)
Neoadjuvant Hormonal Therapy
von Minckwitz et al., 2007ALL (pCR)ER+ (pCR)ER- (pCR)
HER2+HER2-HER2+HER2-HER2+HER2-
TAM+0%10.7%0%0%0%24.2%
TAM-8.7%9.6% 9.1%2.2%8.3%21.4%
Adjuvant Hormonal Therapy
Rasmussen et al., 2008, Mauriac et al., 2007Not reported
Dowsett et al., 2008Not reported
Ryden et al., 2005Not reported
Knoop et al., 2001Not reported
Metastatic Hormonal Therapy
Arpino et al., 2004GrpNcCR+cPR+cSDPDNETestpComments
HER2-10456%44%χ2NS
HER2+3247%53%

Abbreviations: cCR: clinical complete response; cPR: clinical partial response; ER: cSD: clinical stable disease; estrogen-receptor; NE: not evaluable; NS: not significant; PD: progressive disease; SD: stable disease;

From: 3, Results and Conclusions

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.